Site-specific Activation

Site-Specific Activation is a prodrug design strategy in which biologically inert peptide derivatives are selectively converted into their active therapeutic forms at predetermined physiological locations through localized biochemical or environmental triggers, thereby distinguishing it from systemic or non-targeted activation mechanisms.

97

Publications

9.2K

Citations

490

Authors

186

Institutions

Publications per year

2017–2026

26

Authors

490

  1. LN
    Louis N. Jungheim

    Eli Lilly (United States), United States

    3 publications · 130 citations

    3

    h-index

  2. SD
    Stephen D. Mikolajczyk

    Beckman Coulter Foundation, United States

    3 publications · 130 citations

    3

    h-index

  3. JJ
    James J. Starling

    Eli Lilly (United States), United States

    3 publications · 130 citations

    3

    h-index

  4. HJ
    Hidde J. Haisma

    University of Groningen, Netherlands

    3 publications · 115 citations

    3

    h-index

  5. TA
    Timothy A. Shepherd

    Eli Lilly (United States), United States

    3 publications · 130 citations

    3

    h-index

1–5 of 490

Venues

  1. Journal of Biological Chemistry

    JBC · 8 publications · 363 citations

    8

    h-index

  2. Molecular and Cellular Biology

    MCB · 6 publications · 326 citations

    6

    h-index

  3. FEBS Letters

    3 publications · 115 citations

    3

    h-index

  4. Applied Catalysis B: Environmental

    3 publications · 265 citations

    3

    h-index

  5. Chemical Communications

    ChemComm · 3 publications · 108 citations

    3

    h-index

1–5